Abstract A series of 5′‐ O ‐ acyl derivatives (2a‐e) of 5‐ethyl‐2′‐deoxyuridine (EDU, EtUdR) were prepared by direct acylation of the parent nucleoside 1 in pyridine/ N,N ‐dimethylformamide (DMF). These compounds, designed as prodrugs of 1 , offer a wider range of solubilities and lipophilicities than 1. The antiviral activities (against herpes simplex virus types 1 and 2) of all compounds were determined in primary rabbit kidney (PRK) cell cultures.
The pharmacokinetics of the newly developed anti-herpes agent, E-5-(2-bromovinyl)-2'-deoxyuridine, was compared with that of the standard anti-herpes drug 5-iodo-2'-deoxyuridine. Both compounds were administered to mice at 100 mg/kg by either the intraperitoneal, subcutaneous, or oral route. The active blood drug levels achieved by E-5-(2-bromovinyl)-2'-deoxyuridine were considerably higher than those attained by 5-iodo-2'-deoxyuridine (serum peak concentrations: 40 to 100 and 4 to 10 mug/ml, respectively). Active blood drug levels could still be found 320 min after oral administration of E-5-(2-bromovinyl)-2'-deoxyuridine.
No abstract is provided for this article.
Abstract Aus dem Iod‐uridin (I) wird über die Carbonsäure (II) das Bromvinyl‐ uridin (IIIa) hergestellt, das im Vergleich zum Bromvinyl‐uracil (IIIb) auf anti‐.